Future Perspectives in the Treatment of Chronic Lymphocytic Leukemia

Opinion
Video

Concluding their discussion, Drs Advani, Parrondo, and Chanan-Khan conclude that second-generation BTK inhibitors are the preferred first-line treatment in patients with chronic lymphocytic leukemia due to better efficacy and lower cardiovascular risk, with emerging therapies promising even better outcomes.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video